MedTrace Logo

Aliskiren and Muscle Sympathetic Nerve Activity

NCT00719316 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2010-01-14

No results posted yet for this study

Summary

The central hypothesis of this project is that Aliskiren causes a substantial decrease in MSNA in hypertensive patients with CKD.

Conditions

Interventions

DRUG

Aliskiren

Aliskiren 300mg per day for 6 weeks

Sponsors & Collaborators

  • UMC Utrecht

    lead OTHER

Principal Investigators

  • P. J. Blankestijn, MD, PhD · UMC Utrecht

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
25 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2009-07-31
Completion
2010-01-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00719316 on ClinicalTrials.gov